SOURCE: NexMed, Inc.

June 12, 2006 10:53 ET

NexMed Appoints Vivian Liu as Chief Operating Officer

EAST WINDSOR, NJ -- (MARKET WIRE) -- June 12, 2006 -- NexMed, Inc. (NASDAQ: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, today announced that Vivian Liu, the Company's Executive Vice President has also been appointed to serve as its Chief Operating Officer, effective immediately. In her new position, Ms. Liu will oversee NexMed's day-to-day operations.

Ms. Liu joined NexMed in 1994, and has served in various executive positions including Chief Financial Officer from 1999 to December 2005. Prior to joining the Company, Ms. Liu served as Senior Economic Attache at the Delegation du Quebec in Los Angeles. Ms. Liu received her MPA in International Finance from the University of Southern California and her BA from the University of California, Berkeley.

Richard Berman, NexMed's CEO, said, "With Vivian's new appointment, we have solidified our management team. Combined with the capital we have raised this year, we have laid a firm foundation for future growth. We now focus our efforts on developing significant new partnerships to bring our other lead drug candidates through the approval process and into the market."

Len Oppenheim, NexMed's Chairman of the Board, commented, "Much credit must be given to Richard, Vivian and Mark Westgate, our CFO, for managing a very successful cost-cutting program, while at the same time preserving and maintaining a productive R&D program. As we continue to make progress in the operation of NexMed, I will focus my efforts on gaining NexMed greater exposure within the investment community."

About NexMed, Inc.

NexMed, an innovative drug developer, offers large pharmaceutical companies the opportunity to save considerably on R&D costs, develop new patient-friendly transdermal products, and extend patent lifespans and brand equity, through participation in early stage licensing and development partnerships. NexMed currently has a host of medicines in development, such as treatments for nail fungus, sexual disorders and more, all based on its proprietary NexACT® drug delivery technology.

Contact Information

  • Company Contact:
    Deborah Carty
    NexMed, Inc.
    (609) 371-8123, ext: 159
    Email Contact

    Investor Relations:
    Melody Carey
    Rx Communications Group, LLC
    (917) 322-2568
    Email Contact